Offering proceeds to be used for research and development activities
By Devika Patel
Knoxville, Tenn., July 31 - Trovagene, Inc. said it completes a $15 million registered direct offering of stock.
The company sold common shares at $7.00 apiece. The per-share purchase price is a 12.61% discount to $8.01, the closing price of the stock on July 30.
Proceeds will be used for research and development activities, working capital and other general corporate purposes.
Trovagene is a molecular diagnostic company in San Diego.
| Issuer: | Trovagene, Inc.
|
| Issue: | Common stock
|
| Amount: | $15 million
|
| Price: | $7.00
|
| Warrants: | No
|
| Settlement date: | July 31
|
| Stock symbol: | Nasdaq: TROV
|
| Stock price: | $8.01 at close July 30
|
| Market capitalization: | $121.34 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
